ArticleJournal of clinical microbiology2012
Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Misleading presentation of tuberculosis in a child with CGD revealing invasive aspergillosis: A molecularly confirmed case.IDCases · 2026Article
- Functional neutrophil disorders: Chronic granulomatous disease and beyond.Immunological reviews · 2024Review
- Know the enemy and know yourself: Addressing cryptic fungal pathogens of humans and beyond.PLoS pathogens · 2023Article
- Updating the taxonomy ofStudies in mycology · 2020Article
- Annotated Genome Sequence ofMicrobiology resource announcements · 2020Article
- Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease.Pediatric health, medicine and therapeutics · 2020Review
- Efficacy of Olorofim (F901318) againstAntimicrobial agents and chemotherapy · 2019Article
- From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature.Journal of fungi (Basel, Switzerland) · 2018Review
- EmergingOpen forum infectious diseases · 2018Review
- Infectious Complications in Patients With Chronic Granulomatous Disease.Journal of the Pediatric Infectious Diseases Society · 2018Review
- Article
- A Review of Chronic Granulomatous Disease.Advances in therapy · 2017Review
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Name Changes for Fungi of Medical Importance, 2012 to 2015.Journal of clinical microbiology · 2017Review
- Aspergillosis in Chronic Granulomatous Disease.Journal of fungi (Basel, Switzerland) · 2016Review
- Genetic Analysis Using an Isogenic Mating Pair of Aspergillus fumigatus Identifies Azole Resistance Genes and Lack of MAT Locus's Role in Virulence.PLoS pathogens · 2015Article
- Extrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergillus Section Fumigati.Frontiers in microbiology · 2015Review
- Genetic relatedness versus biological compatibility between Aspergillus fumigatus and related species.Journal of clinical microbiology · 2014Article
- Paravertebral mushroom: identification of a novel species of Phellinus as a human pathogen in chronic granulomatous disease.Journal of clinical microbiology · 2014Article
- Ochratoxin production and taxonomy of the yellow aspergilli (Aspergillus section Circumdati).Studies in mycology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
The most common cause of invasive aspergillosis (IA) in patients with chronic granulomatous disease (CGD) is Aspergillus fumigatus followed by A. nidulans; other aspergilli rarely cause the disease. Here we review two clinical cases of fatal IA in CGD patients and describe a new etiologic agent of IA refractory to antifungal therapy. Unlike typical IA caused by A. fumigatus, the disease caused by the new species was chronic and spread from the lung to multiple adjacent organs. Mycological characteristics and the phylogenetic relationship with other aspergilli based on the sequence analysis of Mcm7, RPB2, and Tsr1 indicated that the new species, which we named as A. tanneri, belongs to Aspergillus section Circumdati. The species has a higher amphotericin B, voriconazole, and itraconazole MIC and causes more chronic infection in CGD mice than A. fumigatus. This is the first report documenting IA in CGD patients caused by a species belonging to the Aspergillus section Circumdati that is inherently resistant to azoles and amphotericin B. Unlike the results seen with many members of Aspergillus section Circumdati, ochratoxin was not detected in filtrates of cultures grown in various media. Our phenotypic and genetic characterization of the new species and the case reports will assist future diagnosis of infection caused by A. tanneri and lead to more appropriate patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.